InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Combs Andrew, Dirigeant. Director active across 1 companies, notably Prelude Therapeutics Inc. Cumulatively, 3 reports have been logged. Total volume traded: €86k. The latest transaction was disclosed on 31 March 2022 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations3 total
€61,55636,062 shares@ €1.7070.017% mcap41.8% of flow
Common Stock
SEC:0001209191-22-022524:0·
€42,8584,000 shares@ €10.71440.012% mcap100.0% of flow
Common Stock
SEC:0001209191-21-069796·
Ideal exit: 9 Sept 2022 (T+270)
€42,8584,000 shares@ €10.71440.012% mcap29.1% of flow
Common Stock
SEC:0001209191-21-069796:0·
Ideal exit: 9 Sept 2022 (T+270)
3 of 3 declarations
About Combs Andrew
Andrew Combs is Executive Vice President and Head of Chemistry at Prelude Therapeutics Inc. He oversees the company's research and development initiatives, focusing on innovation in the therapeutic area.
